Table 6a. Anticoagulant Therapy: Selected Clinical Data

Last Updated: July 21, 2023

The clinical trials described in this table do not represent all the trials that the Panel reviewed while developing the recommendations for anticoagulant therapy. The studies summarized below are those that have had the greatest impact on the Panel’s recommendations.

Table 6a. Anticoagulant Therapy: Selected Clinical Data
Methods	Results	Limitations and Interpretation
ATTACC/ACTIV-4a/REMAP-CAP: Multiplatform, Open-Label RCT of Therapeutic Anticoagulation in Noncritically Ill, Hospitalized Patients With COVID-19 in 9 Countries¹
Key Inclusion Criterion Hospitalized with laboratory-confirmed SARS-CoV-2 infection without need for HFNC oxygen, NIV, MV, vasopressors, or inotropes Key Exclusion Criteria Hospital discharge expected in ≤72 hours Requirement for therapeutic anticoagulation or dual antiplatelet therapy High bleeding risk Interventions Therapeutic UFH or LMWH for 14 days or until hospital discharge, whichever came first (n = 1,190) SOC, which included prophylactic UFH or LMWH (n = 1,054) Primary Endpoint Organ support-free days at Day 21, as measured by an OS Key Secondary Endpoints Survival until hospital discharge Hospital LOS Thrombosis or major bleeding events	Participant Characteristics Median age 59 years; 59% men; median BMI 30 52% with HTN; 30% with DM; 11% with CVD 66% required low-flow oxygen D-dimer: 48.4% <2 times ULN 28.4% ≥2 times ULN 23.1% unknown 62% on corticosteroids; 36% on RDV Primary Outcomes Therapeutic anticoagulation superior to SOC for organ support-free days (aOR 1.27; 95% CrI, 1.03–1.58; 99% posterior probability) 4% absolute difference in survival until hospital discharge without organ support that favored therapeutic arm (95% CrI, 0.5–7.2) Outcome consistent across D-dimer stratum Secondary Outcomes Survival until hospital discharge: 92% in both arms No difference between arms in hospital LOS (aOR 1.03; 95% CrI, 0.94–1.13) Thrombosis: 1% in therapeutic arm vs. 2% in SOC arm Major bleeding events: 2% in therapeutic arm vs. 1% in SOC arm	Key Limitations Open-label study Anticoagulation dose varied in SOC arm (27% received intermediate-dose thromboprophylaxis) Varied criteria for ICU care and expected hospital LOS Only enrolled 17% of screened patients Interpretation Therapeutic heparin increased the number of organ support-free days and decreased the number of patients requiring organ support. Therapeutic heparin did not significantly affect hospital LOS or the number of major thrombosis events or deaths. Major bleeds occurred 1% more frequently in therapeutic arm than in SOC arm.
RAPID: Open-Label RCT of Therapeutic Heparin in Moderately Ill, Hospitalized Patients With COVID-19 in 6 Countries²
Key Inclusion Criteria Hospitalized with COVID-19 and D-dimer ≥2 times ULN or any elevated D-dimer level and SpO₂ ≤93% on room air Hospitalized <5 days Key Exclusion Criteria Indication for therapeutic anticoagulation Dual antiplatelet therapy High bleeding risk Interventions Therapeutic UFH or LMWH for 28 days or until discharge or death (n = 228) Prophylactic UFH or LMWH for 28 days or until discharge or death (n = 237) Primary Endpoint Composite of ICU admission, NIV or MV, or death up to 28 days Key Secondary Endpoints All-cause death Mean number of organ support-free days VTE Major bleeding event Mean number of hospital-free days alive	Participant Characteristics Median age 60 years; 57% men; mean BMI 30 48% with HTN; 34% with DM; 7% with CVD 91% had hypoxia; 6% received HFNC oxygen D-dimer: 49% <2 times ULN 51% ≥2 times ULN 69% on corticosteroids Primary Outcome Composite of ICU admission, NIV or MV, or death up to 28 days: 16% in therapeutic arm vs. 22% in prophylactic arm (OR 0.69; 95% CI, 0.43–1.10) Secondary Outcomes All-cause death: 2% in therapeutic arm vs. 8% in prophylactic arm (OR 0.22; 95% CI, 0.07–0.65) Mean number of organ support-free days: 26 in therapeutic arm vs. 24 in prophylactic arm (OR 1.41; 95% CI, 0.9–2.21) No difference between arms for VTE (1% in therapeutic arm vs. 3% in prophylactic arm) or major bleeding events (1% in therapeutic arm vs. 2% in prophylactic arm) Mean number of hospital-free days alive: 20 in therapeutic arm vs. 18 in prophylactic arm (OR 1.09; 95% CI, 0.79–1.50)	Key Limitations Open-label study Only enrolled 12% of screened patients Interpretation Compared to prophylactic heparin, therapeutic heparin reduced mortality (a secondary endpoint) but had no effects on the composite primary endpoint of ICU admission, the need for NIV or MV, or death up to 28 days. There were no differences between the arms in the percentages of patients who experienced major bleeding events or VTE.
HEP-COVID: Open-Label RCT of Therapeutic Heparin in High-Risk, Hospitalized Patients With COVID-19 in the United States³
Key Inclusion Criteria Hospitalized with COVID-19 and required supplemental oxygen D-dimer >4 times ULN or sepsis-induced coagulopathy score of ≥4 Hospitalized <72 hours Key Exclusion Criteria Indication for therapeutic anticoagulation Dual antiplatelet therapy High bleeding risk CrCl <15 mL/min Interventions Therapeutic LMWH until hospital discharge or primary endpoint met (n = 129) Usual care of prophylactic or intermediate-dose LMWH until hospital discharge or primary endpoint met (n = 124) Primary Endpoint Composite of VTE, ATE, or death from any cause within 32 days of randomization Key Safety Endpoint Major bleeding events	Participant Characteristics Median age 67 years; 54% men; mean BMI 30 60% with HTN; 37% with DM; 75% with CVD 64% received oxygen via nasal cannula; 15% received high-flow oxygen or NIV; 5% received MV 80% on corticosteroids Primary Outcomes Composite of VTE, ATE, or death within 32 days: 29% in therapeutic arm vs. 42% in usual care arm (relative risk 0.68; 95% CI, 0.49–0.96) Death: 19% in therapeutic arm vs. 25% in usual care arm (relative risk 0.78; 95% CI, 0.49–1.23) Thrombotic events: 11% in therapeutic arm vs. 29% in usual care arm (relative risk 0.37; 95% CI, 0.21–0.66) Non-ICU stratum composite of VTE, ATE, or death within 32 days: 17% in therapeutic arm vs. 36% in usual care arm (relative risk 0.46; 95% CI, 0.27–0.81) Key Safety Outcomes Major bleeding events within 32 days: 5% in therapeutic arm vs. 2% in usual care arm (relative risk 2.88; 95% CI, 0.59–14.02) Non-ICU stratum major bleeding events within 32 days: 2% in both arms	Key Limitations Open-label study Only enrolled 2% of screened patients Interpretation Compared to usual care, therapeutic LMWH reduced the incidence of VTE, ATE, and death. Among patients who were not in the ICU, therapeutic LMWH significantly reduced the percentage of patients who experienced thrombotic events and did not increase the percentage of patients who experienced major bleeding events.
ACTION: Open-Label RCT of Therapeutic Rivaroxaban in Hospitalized Patients With COVID-19 in Brazil⁴
Key Inclusion Criteria Hospitalized for COVID-19 with elevated D-dimer level Symptoms for ≤14 days Key Exclusion Criteria Indication for therapeutic anticoagulation CrCl <30 mL/min P2Y12 inhibitor therapy or aspirin >100 mg High bleeding risk Interventions Therapeutic anticoagulation for 30 days: rivaroxaban 15 mg or 20 mg daily; if clinically unstable, enoxaparin 1 mg/kg twice daily or UFH (n = 311) Usual care prophylactic anticoagulation with enoxaparin or UFH during hospitalization (n = 304) Primary Endpoint Hierarchical composite of time to death, hospital duration, or oxygen use duration through Day 30 Key Secondary Endpoints Thrombosis, with and without all-cause death Mortality Bleeding events	Participant Characteristics Median age 57 years; 60% men; mean BMI 30 49% with HTN; 24% with DM; 5% with coronary disease Critically ill: 7% in therapeutic arm vs. 5% in usual care arm 75% required oxygen: 60% low-flow oxygen; 8% HFNC oxygen; 1% NIV; 6% MV 83% on corticosteroids Primary Outcome No difference between arms in the composite of time to death, hospital duration, or oxygen use duration through Day 30 (win ratio 0.86; 95% CI, 0.59–1.22) Secondary Outcomes No difference between therapeutic and usual care arms in: Thrombosis: 7% vs. 10% Mortality: 11% vs. 8% Any bleeding: 12% in therapeutic arm vs. 3% in usual care arm Major bleeding: 3% in therapeutic arm vs. 1% in usual care arm Clinically relevant, nonmajor bleeding: 5% in therapeutic arm vs. 1% in usual care arm	Key Limitations Open-label study Only enrolled 18% of screened patients Therapeutic rivaroxaban was administered for a longer duration than prophylactic anticoagulation (30 days vs. a mean duration of 8 days). Interpretation When compared with usual care, therapeutic rivaroxaban did not reduce mortality, hospital duration, oxygen use duration, or the percentage of patients who experienced thrombosis. Patients who received therapeutic rivaroxaban had more clinically relevant nonmajor bleeding events than those who received usual care. The longer duration of therapy in the rivaroxaban arm may have influenced the difference in bleeding events.
FREEDOM: RCT of Anticoagulation Strategies in Noncritically Ill Patients Who Were Hospitalized With COVID-19 in 10 Countries⁵
Key Inclusion Criterion Hospitalized for symptomatic COVID-19 for <48 hours Key Exclusion Criteria Indication for therapeutic anticoagulation CrCl <30 mL/min P2Y12 inhibitor therapy or aspirin >100 mg per day Anticipated hospitalization for <72 hours Interventions Therapeutic apixaban 5 mg twice daily (n = 1,121) Therapeutic enoxaparin 1 mg/kg twice daily (n = 1,136) Usual care prophylactic enoxaparin (n = 1,141) Primary Endpoint 30-day composite of all-cause mortality, need for ICU-level care, systemic thromboembolism, or ischemic stroke. Endpoint assessed for the combined therapeutic arms vs. the prophylactic arm. Key Secondary Endpoints All-cause mortality Bleeding events (BARC type 3 or 5)	Participant Characteristics Median age 52 years; 59% men; mean BMI 26 32% with HTN; 19% with DM 22% on corticosteroids; 10% on RDV Primary Outcome 30-day composite outcome: 11.3% in combined therapeutic arms vs. 13.2% in prophylactic arm (HR 0.85; 95% CI, 0.69–1.04; P = 0.11) Primary endpoint was not statistically significant when therapeutic enoxaparin or apixaban were compared to prophylactic enoxaparin. Secondary Outcomes All-cause mortality: 4.9% in therapeutic enoxaparin arm vs. 7.0% in prophylactic enoxaparin arm (HR 0.69; 95% CI, 0.49–0.99) All-cause mortality: 5.0% in therapeutic apixaban arm vs. 7.0% in prophylactic enoxaparin arm (HR 0.7; 95% CI, 0.49–0.99) BARC type 3 or 5 bleeding: 0.4% in combined therapeutic arms vs. 0.1% in prophylactic arm (IRR 3.96; 95% CI, 0.50–31.27)	Key Limitations Open-label study Terminated early due to slow recruitment (3,452 of 3,600 planned patients recruited) Minimal treatment with RDV or DEX as SOC for COVID-19 Interpretation When compared with prophylactic enoxaparin, therapeutic apixaban or therapeutic enoxaparin did not reduce 30-day mortality, the need for ICU-level care, thromboembolism, or ischemic stroke. Fewer patients died in the therapeutic enoxaparin and therapeutic apixaban arms than in the prophylactic enoxaparin arm. There were no statistically significant differences between the arms in the number of severe bleeding events.
COVID-PACT: Open-Label RCT of Full-Dose Versus Prophylactic-Dose Anticoagulation in Adults With COVID-19 Who Were Receiving Intensive Care Unit-Level Care in the United States⁶
Key Inclusion Criteria Aged ≥18 years Acute SARS-CoV-2 infection ICU-level care for ≤96 hours prior to randomization Key Exclusion Criteria Ongoing or planned use of full-dose anticoagulation or dual antiplatelet therapy High risk of bleeding events History of HIT Ischemic stroke within 2 weeks Interventions Full-dose anticoagulation until Day 28 or hospital discharge, whichever came first (n = 197) Prophylactic anticoagulation (n = 193) Eligible patients were also randomized 1:1 to receive clopidogrel or no antiplatelet therapy (n = 292) Primary Endpoint Composite of VTE or ATE events, including death due to VTE or ATE, PE, clinically evident DVT, MI, ischemic stroke, systemic embolic event or acute limb ischemia, or clinically silent DVT through hospital discharge or Day 28 Key Secondary Endpoint Individual outcomes listed above, with the exception of clinically silent DVT Safety Endpoints Fatal or life-threatening bleeding events Moderate or severe bleeding events	Participant Characteristics Median age 61 years; 41% women; 71% White 99% required HFNC oxygen, NIV, or MV; 15% required MV (41% required MV during the study) 31% to 37% crossed over to an alternative study treatment during the study Primary Outcome Composite of VTE or ATE events: 12% in full-dose anticoagulation arm vs. 6% in prophylactic anticoagulation arm (win ratio 1.95; 95% CI, 1.08–3.55; P = 0.028) Secondary Outcome Clinically evident VTE or ATE: 10% in full-dose anticoagulation arm vs. 6% in prophylactic anticoagulation arm (win ratio 1.79; 95% CI, 0.92–3.47; P = 0.087) Safety Outcomes No fatal bleeding events in either arm Life-threatening bleeding events: 4 (2.1%) in full-dose anticoagulation arm vs. 1 (0.5%) in prophylactic anticoagulation arm (P = 0.19) Moderate or severe bleeding events: 15 (7.9%) in full-dose anticoagulation arm vs. 1 (0.5%) in prophylactic anticoagulation arm (P = 0.002)	Key Limitations Open-label study (adjudication committee members were blinded to the study arms) Stopped early because the decreasing number of ICU admissions for patients with COVID-19 made recruitment difficult. There was an unequal crossover between the arms, with a greater crossover from the prophylactic anticoagulation arm to the full-dose anticoagulation arm. Interpretation Among patients with COVID-19 who required ICU-level care, patients who received full-dose anticoagulation had fewer VTE or ATE events but no survival benefit compared to those who received prophylactic anticoagulation. The prevalence of moderate or severe bleeding events was higher among patients who received full-dose anticoagulation than among those who received prophylactic anticoagulation.
REMAP-CAP/ACTIV-4a/ATTACC: Multiplatform, Open-Label RCT of Therapeutic Anticoagulation in Critically Ill, Hospitalized Patients With COVID-19 in 20 Countries⁷
Key Inclusion Criteria Hospitalized with severe COVID-19 and receiving HFNC oxygen, NIV, MV, ECMO, vasopressors, or inotropes Hospitalized <72 hours (ACTIV-4a, ATTACC) or <14 days (REMAP-CAP) Key Exclusion Criteria Hospital discharge expected within 72 hours Requirement for therapeutic anticoagulation or dual antiplatelet therapy High bleeding risk Interventions Therapeutic UFH or LMWH for 14 days or until discharge, whichever came first (n = 534) Usual care (n = 564) Primary Endpoint Number of organ support-free days by Day 21 Key Secondary Endpoints Survival to hospital discharge Any thrombosis Composite of major thrombotic events or death Bleeding events	Participant Characteristics Median age 60 years; 70% men; median BMI 30 24% with chronic respiratory disease; 33% with DM; 10% with chronic kidney disease; 8% with severe CVD 32% required HFNC oxygen; 38% required NIV; 29% required MV 18% on vasopressors; 82% on corticosteroids; 32% on RDV Primary Outcome Median number of organ support-free days by Day 21: 4 in therapeutic arm vs. 5 in usual care arm (aOR 0.83; 95% CrI, 0.67–1.03; 99.9% posterior probability of futility; OR < 1.2) Secondary Outcomes No difference between therapeutic and usual care arms in: Survival to hospital discharge: 63% vs. 65% (aOR 0.84; 95% CrI, 0.64–1.11) Thrombosis: 6% vs. 10% Major thrombotic events or death: 41% in both arms Major bleeding events: 4% vs. 2% (aOR 1.48; 95% CrI, 0.75–3.04)	Key Limitations Open-label study Anticoagulation dose varied in usual care arm (i.e., 51% intermediate, 2% subtherapeutic, 5% therapeutic). Inclusion criteria for hospital LOS and ICU-level care differed across trials. Trial stopped for futility. Interpretation In patients who required ICU-level care, therapeutic heparin did not reduce the duration of organ support or mortality. Although the differences were not significant, patients who received therapeutic anticoagulation had more bleeding events and fewer thrombotic events than patients who received usual care.
INSPIRATION: Open-Label RCT of Intermediate-Dose Versus Prophylactic-Dose Anticoagulation in Patients With COVID-19 in Intensive Care Units in Iran⁸
Key Inclusion Criteria Admitted to ICU Hospitalized <7 days Key Exclusion Criteria Life expectancy <24 hours Indication for therapeutic anticoagulation Overt bleeding Interventions Intermediate-dose anticoagulation: enoxaparin 1 mg/kg once daily (n = 276) Prophylactic-dose anticoagulation (n = 286) Primary Endpoint Composite of adjudicated acute VTE, ATE, the need for ECMO, or all-cause mortality within 30 days Key Secondary Endpoints All-cause mortality VTE Bleeding events	Participant Characteristics Median age 62 years; 58% men; median BMI 27 44% with HTN; 28% with DM; 14% with coronary artery disease 32% required NIV; 20% required MV 23% on vasopressors; 93% on corticosteroids; 60% on RDV Primary Outcome Composite of adjudicated acute VTE, ATE, the need for ECMO, or all-cause mortality: 46% in therapeutic arm vs. 44% in prophylactic arm (OR 1.06; 95% CI, 0.76–1.48) Secondary Outcomes No difference between therapeutic and prophylactic arms in: All-cause mortality: 43% vs. 41% VTE: 3% in both arms Major bleeding events and clinically relevant nonmajor bleeding events: 6.3% vs. 3.1% (OR 2.02; 95% CI, 0.89–4.61)	Key Limitations Open-label study Not all patients received ICU-level care. Interpretation Intermediate-dose anticoagulation did not significantly reduce the occurrence of VTE and ATE, the need for ECMO, or mortality. Although the difference was not significant, patients who received intermediate-dose anticoagulation had more bleeding events than patients who received usual care.
OVID: Open-Label RCT of Low-Molecular-Weight Heparin for Thromboprophylaxis in Symptomatic, Nonhospitalized Patients With COVID-19 in Germany and Switzerland⁹
Key Inclusion Criteria Aged ≥50 years Positive SARS-CoV-2 test result within past 5 days Respiratory symptoms or temperature ≥37.5°C Key Exclusion Criteria Severe renal or hepatic dysfunction Severe anemia or recent major bleeding Dual antiplatelet therapy Interventions Enoxaparin 40 mg SUBQ once daily for 14 days (n = 234) SOC (n = 238) Primary Endpoint Composite of any untoward hospitalization or all-cause death by Day 30 Key Secondary Endpoint Composite of major arterial and venous cardiovascular events by Day 30 Bleeding events	Participant Characteristics Median age 57 years; 46% women; 96% White Median time from COVID-19 diagnosis to randomization: 3 days 24% with HTN; 8% with DM; 5% with CVD 9.5% received at least 1 dose of a COVID-19 vaccine Primary Outcome Composite of any untoward hospitalization or all-cause death by Day 30: 8 (3%) in enoxaparin arm vs. 8 (3%) in SOC arm (adjusted relative risk 0.98; 95% CI, 0.37–2.56; P = 0.96) Key Secondary Outcomes Composite of major arterial and venous cardiovascular events by Day 30: 2 (1%) in enoxaparin arm vs. 4 (2%) in SOC arm (relative risk 0.51; 95% CI, 0.09–2.74) No major or clinically relevant nonmajor bleeding events occurred	Key Limitations Open-label study Study terminated early due to a low probability that enoxaparin would be superior to the standard of care for the primary outcome. Interpretation Thromboprophylaxis with enoxaparin did not reduce the risk of hospitalization or death among nonhospitalized, symptomatic patients with COVID-19.
ETHIC: Open-Label RCT of Low-Molecular-Weight Heparin for Thromboprophylaxis in Symptomatic Outpatients With COVID-19 in Belgium, Brazil, India, South Africa, Spain, and the UK¹⁰
Key Inclusion Criteria Aged ≥30 years RT-PCR-confirmed SARS-CoV-2 infection, with symptoms for ≤9 days ≥1 risk factor for severe disease Key Exclusion Criteria Receipt of COVID-19 vaccination eGFR <30 mL/min Anticoagulant or antiplatelet therapy, except low-dose aspirin Interventions Enoxaparin 40 mg SUBQ daily (for patients weighing <100 kg) or enoxaparin 40 mg SUBQ twice daily (for patients weighing ≥100 kg), self-administered for 21 days (n = 105) SOC (n = 114) Primary Endpoint Composite of all-cause hospitalization or all-cause mortality by Day 21 Key Secondary Endpoints VTE by Day 90 Bleeding events by Day 50	Participant Characteristics Median age 59 years; 56% men Median time from first symptom to randomization: 5 days Primary Outcomes Composite of all-cause hospitalization or all-cause mortality by Day 21: 12 (11%) in enoxaparin arm vs. 12 (11%) in SOC arm (HR 1.09; 95% CI, 0.49–2.43; P = 0.83) Patients who required hospitalization: 12 in enoxaparin arm vs. 12 in SOC arm Hospitalized patients who required acute medical care or ICU admission: 4 in enoxaparin arm vs. 0 in SOC arm Key Secondary Outcomes VTE by Day 90: 1 (1%) in enoxaparin arm vs. 2 (2%) in SOC arm Bleeding events by Day 50: 2 (2%) in enoxaparin arm vs. 2 (2%) in SOC arm	Key Limitations Open-label study Study terminated early because of low event rate and lack of efficacy. Interpretation This study demonstrated no benefit of prophylaxis with LMWH in outpatients with COVID-19 who were at risk of progressing to severe disease.
ACTIV-4C: Double-Blind RCT of 30 Days of Apixaban After Hospital Discharge in Patients With COVID-19 in the United States¹¹
Key Inclusion Criteria Hospitalized >48 hours with confirmed SARS-CoV-2 infection within 2 weeks of admission Platelet count >50 x 10⁹ cells/L and hemoglobin >8 g/dL Key Exclusion Criteria Indication for therapeutic or prophylactic anticoagulation at discharge Ischemic stroke, intracranial bleed, or neurosurgery within 3 months Bleeding within past 30 days Major surgery within 14 days Inherited or active acquired bleeding disorder Interventions Apixaban 2.5 mg twice daily for 30 days, starting at hospital discharge (n = 610) Placebo (n = 607) Primary Endpoint Composite of death, ATE, or VTE by Day 30 Key Safety Endpoint Bleeding events	Participant Characteristics Median age 54 years; 50% men; 27% Black, 17% Hispanic 15% were receiving antiplatelet therapy At discharge, 16% were prescribed antiplatelet therapy; 93% received aspirin. Primary Outcome Composite of death, ATE, or VTE by Day 30: 13 (2.1%) in apixaban arm vs. 14 (2.3%) in placebo arm (relative risk 0.92; 95% CI, 0.44–1.95; P = 0.85) Safety Outcomes Major bleeding events: 2 (0.4%) in apixaban arm vs. 1 (0.2%) in placebo arm (relative risk 2.00; 95% CI, 0.18–22.03) Clinically relevant nonmajor bleeding events: 3 (0.6%) in apixaban arm vs. 6 (1.1%) in placebo arm (relative risk 0.50; 95% CI, 0.13–1.99)	Key Limitation Trial was terminated early due to a low event rate and because the decreasing number of hospitalizations for people with COVID-19 made recruitment difficult. Interpretation Incidence of death or thromboembolism was low in this cohort of patients. Because the trial was terminated early, the results were imprecise, and the study was inconclusive.
MICHELLE: Open-Label RCT of Using Rivaroxaban After Hospital Discharge in Patients With COVID-19 Who Were at High Risk of Venous Thromboembolism in Brazil¹²
Key Inclusion Criteria Hospitalized for ≥3 days with confirmed SARS-CoV-2 infection Increased risk of VTE, defined as an IMPROVE VTE score at hospital discharge of >4 or 2–3 with a D-dimer level >500 ng/mL Key Exclusion Criterion Suspicion or confirmation of a thrombotic event Interventions Rivaroxaban 10 mg PO once daily for 35 days, starting at hospital discharge (n = 159) No anticoagulation (n = 159) Primary Endpoint Composite of symptomatic or fatal VTE, asymptomatic VTE on bilateral lower-limb venous ultrasound and CTPA, symptomatic ATE, or cardiovascular death by Day 35 Key Secondary Endpoints Symptomatic or fatal VTE Composite of symptomatic VTE, MI, non-hemorrhagic stroke, or cardiovascular death Key Safety Endpoint Bleeding events	Participant Characteristics Median age 57 years; 60% men While hospitalized, 86% received thromboprophylaxis with enoxaparin, 14% received unfractionated heparin, and 5% received antiplatelet therapy. Primary Outcomes Primary composite outcome by Day 35: 5 (3%) in rivaroxaban arm vs. 15 (9%) in no anticoagulation arm (relative risk 0.33; 95% CI, 0.12–0.90; P = 0.03) Difference driven mainly by incidence of pulmonary embolism (2 in rivaroxaban arm vs. 10 in no anticoagulation arm) Key Secondary Outcomes Symptomatic or fatal VTE: 1 (0.6%) in rivaroxaban arm vs. 8 (5.0%) in no anticoagulation arm (relative risk 0.13; 95% CI, 0.02–0.99; P = 0.049) Composite of symptomatic VTE, MI, stroke, or cardiovascular death: 1 (0.6%) in rivaroxaban arm vs. 9 (5.7%) in no anticoagulation arm (relative risk 0.11; 95% CI, 0.01–0.87; P = 0.036) Safety Outcome No major bleeding events occurred in either arm.	Key Limitations Open-label study with no placebo Not all patients had the protocol-specified CTPA or Doppler ultrasound during the study. However, a higher number of imaging evaluations occurred among the patients in the rivaroxaban arm. Interpretation In patients who were at high risk of VTE, the use of thromboprophylaxis with rivaroxaban 10 mg PO once daily for 35 days improved clinical outcomes when compared with no anticoagulation.
Key: ATE = arterial thromboembolism; BARC = Bleeding Academic Research Consortium; BMI = body mass index; CrCl = creatinine clearance; CTPA = computed tomography pulmonary angiogram; CVD = cardiovascular disease; DEX = dexamethasone; DM = diabetes mellitus; DVT = deep vein thrombosis; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate; HFNC = high-flow nasal cannula; HIT = heparin-induced thrombocytopenia; HTN = hypertension; ICU = intensive care unit; IMPROVE = International Medical Prevention Registry on Venous Thromboembolism; LMWH = low-molecular-weight heparin; LOS = length of stay; MI = myocardial infarction; MV = mechanical ventilation; NIV = noninvasive ventilation; OS = ordinal scale; the Panel = the COVID-19 Treatment Guidelines Panel; PE = pulmonary embolism; PO = oral; RCT = randomized controlled trial; RDV = remdesivir; RT-PCR = reverse transcriptase polymerase chain reaction; SOC = standard of care; SpO₂ = oxygen saturation; SUBQ = subcutaneous; UFH = unfractionated heparin; ULN = upper limit of normal; VTE = venous thromboembolism

References

ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med. 2021;385(9):790-802. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34351721.
Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34649864.
Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612-1620. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34617959.
Lopes RD, de Barros ESPGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397(10291):2253-2263. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34097856.
Stone GW, Farkouh ME, Lala A, et al. Randomized trial of anticoagulation strategies for noncritically ill patients hospitalized with COVID-19. J Am Coll Cardiol. 2023;81(18):1747-1762. Available at: https://pubmed.ncbi.nlm.nih.gov/36889611.
Bohula EA, Berg DD, Lopes MS, et al. Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-PACT. Circulation. 2022;146(18):1344-1356. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36036760.
REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med. 2021;385(9):777-789. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34351722.
INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620-1630. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33734299.
Barco S, Voci D, Held U, et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, Phase 3 trial. Lancet Haematol. 2022;9(8):e585-e593. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35779558.
Cools F, Virdone S, Sawhney J, et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, Phase 3b trial. Lancet Haematol. 2022;9(8):e594-e604. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35779560.
Wang TY, Wahed AS, Morris A, et al. Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization. Ann Intern Med. 2023;176(4):515-523. Available at: https://pubmed.ncbi.nlm.nih.gov/36940444.
Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399(10319):50-59. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34921756.